In last trading session, Neumora Therapeutics Inc. (NASDAQ:NMRA) saw 0.8 million shares changing hands with its beta currently measuring 3.90. Company’s recent per share price level of $12.92 trading at -$0.16 or -1.22% at ring of the bell on the day assigns it a market valuation of $2.07B. That closing price of NMRA’s stock is at a discount of -62.54% from its 52-week high price of $21.00 and is indicating a premium of 35.53% from its 52-week low price of $8.33. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.28 million shares which gives us an average trading volume of 872.32K if we extend that period to 3-months.
For Neumora Therapeutics Inc. (NMRA), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.4 in the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Neumora Therapeutics Inc. (NASDAQ:NMRA) trade information
Neumora Therapeutics Inc.’s shares saw a change of -24.22% in year-to-date performance and have moved 0.00% in past 5-day. Neumora Therapeutics Inc. (NASDAQ:NMRA) showed a performance of 11.67% in past 30-days. Number of shares sold short was 9.52 million shares which calculate 22.58 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 24.5 to the stock, which implies a rise of 47.27% to its current value. Analysts have been projecting 20 as a low price target for the stock while placing it at a high target of 29. It follows that stock’s current price would drop -54.8% in reaching the projected high whereas dropping to the targeted low would mean a loss of -54.8% for stock’s current value.
Neumora Therapeutics Inc. (NMRA) estimates and forecasts
Statistics highlight that Neumora Therapeutics Inc. is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -6.04% of value to its shares in past 6 months, showing an annual growth rate of 58.40% while that of industry is 17.70. Apart from that, the company came raising its revenue forecast for fiscal year 2024.
Neumora Therapeutics Inc. (NASDAQ:NMRA)’s Major holders
Insiders are in possession of 28.05% of company’s total shares while institution are holding 61.25 percent of that, with stock having share float percentage of 85.13%. Investors also watch the number of corporate investors in a company very closely, which is 61.25% institutions for Neumora Therapeutics Inc. that are currently holding shares of the company.
On the other hand, Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Jun 30, 2024 , the former fund manager was holding 2.39 shares of worth $30.88 million or 1.49% of the total outstanding shares. The later fund manager was in possession of 2.25 shares on Aug 31, 2024 , making its stake of worth around $29.09 million in the company or a holder of 1.41% of company’s stock.
